Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38666150 | 1.00 | DPP4 (0.33) | DPP4AAK1HDAC1HDAC2HDAC6 | |
| SCHEMBL27406050 | 0.82 | DPP4 (0.33) | DPP4AAK1HDAC1HDAC2HDAC6 | |
| SCHEMBL4813601 | 0.82 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL9178624 | 0.82 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL8644149 | 0.82 | DPP4 (0.33) | DPP4AAK1HDAC1HDAC2HDAC6 | |
| SCHEMBL4813607 | 0.82 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL13489798 | 0.81 | AAK1 (0.31) | DPP4AAK1 | |
| SCHEMBL7176203 | 0.81 | DPP4 (0.51) | DPP4AAK1HDAC1HDAC2HDAC6 | |
| SCHEMBL18714767 | 0.78 | MMP13 (0.31) | AAK1 | |
| SCHEMBL5345861 | 0.77 | AAK1 (0.35) | AAK1HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-2341886-B1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8278482-B2 | Antimicrobial N-chlorinated compositions | NOVABAY PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100158818-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158818-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NRDC, NHERF1, MPO | DPP4 3451/4885AAK1 3828/4885HDAC1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.